MilWealth Group LLC Invests $490,000 in Abbott Laboratories $ABT

Posted by Francis Steltz on Aug 24th, 2026

MilWealth Group LLC acquired a new stake in Abbott Laboratories (NYSE:ABT – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,403 shares of the healthcare product maker’s stock, valued at approximately $490,000. Abbott Laboratories makes up 0.1% of MilWealth Group LLC’s investment portfolio, making the stock its 12th largest position.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABT. Brighton Jones LLC raised its stake in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC grew its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after acquiring an additional 162 shares during the last quarter. United Bank increased its holdings in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC raised its position in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after acquiring an additional 1,428 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its holdings in shares of Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent research reports. Wells Fargo & Company raised their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Citigroup boosted their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 17th. Finally, TD Cowen reaffirmed a “buy” rating and set a $115.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $118.67.

Read Our Latest Stock Report on ABT

Abbott Laboratories Stock Down 0.0%

Shares of NYSE:ABT opened at $116.62 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The stock has a market capitalization of $201.80 billion, a P/E ratio of 37.74, a PEG ratio of 2.26 and a beta of 0.59. The stock has a 50-day simple moving average of $100.08 and a 200-day simple moving average of $99.98.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.